Proficio Capital Partners LLC Makes New $1.43 Million Investment in Twist Bioscience Co. (NASDAQ:TWST)

Proficio Capital Partners LLC acquired a new position in Twist Bioscience Co. (NASDAQ:TWST) in the 4th quarter, Holdings Channel.com reports. The firm acquired 30,717 shares of the company’s stock, valued at approximately $1,427,000.

Other large investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB purchased a new position in shares of Twist Bioscience in the third quarter valued at $34,000. Van ECK Associates Corp increased its position in shares of Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after buying an additional 267 shares in the last quarter. US Bancorp DE increased its position in shares of Twist Bioscience by 72.0% in the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after buying an additional 601 shares in the last quarter. Beaird Harris Wealth Management LLC purchased a new position in shares of Twist Bioscience in the third quarter valued at $95,000. Finally, KBC Group NV increased its position in shares of Twist Bioscience by 71.4% in the fourth quarter. KBC Group NV now owns 2,942 shares of the company’s stock valued at $137,000 after buying an additional 1,226 shares in the last quarter.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. TD Cowen restated a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. Wolfe Research began coverage on Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. JPMorgan Chase & Co. lifted their price objective on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. Robert W. Baird lifted their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 4th. Finally, Barclays set a $58.00 price objective on Twist Bioscience and gave the stock an “overweight” rating in a research report on Monday, February 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.40.

Twist Bioscience Stock Up 0.8 %

Shares of NASDAQ:TWST opened at $42.05 on Friday. The stock’s 50-day moving average price is $45.41 and its two-hundred day moving average price is $45.21. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of -12.44 and a beta of 2.15.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same period last year, the company earned ($0.75) EPS. The firm’s quarterly revenue was up 24.1% on a year-over-year basis. On average, research analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current year.

Insider Activity

In other news, insider Dennis Cho sold 806 shares of Twist Bioscience stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $39,776.10. Following the transaction, the insider now directly owns 112,221 shares of the company’s stock, valued at $5,538,106.35. The trade was a 0.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Paula Green sold 1,259 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $62,131.65. Following the sale, the senior vice president now owns 132,014 shares in the company, valued at approximately $6,514,890.90. The trade was a 0.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 31,552 shares of company stock valued at $1,500,289 in the last three months. Corporate insiders own 3.01% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.